Three novel treatment options for the treatment of HIV, to be launched in the next two years by Gilead and Tibotec, have the potential for combined sales above $5bn, according to a new study.
The study by Decision Resources expects very high sales values for Gilead’s Quad, Tibotec’s rilpivirine and Gilead / Tibotec’s rilpivirine / emtricitabine / tenofovir fixed-dose combination product.
According to the study, Gilead’s Quad will earn peak-year sales of up to $2.5bn and Gilead / Tibotec’s rilpivirine / emtricitabine / tenofovir will earn peak-year sales of up to $3bn.
The report predicts combined peak-year sales in excess of $5bn in the US, France, Germany, Italy, Spain, UK and Japan.
A major factor behind the predicted robust uptake is the products’ favourable safety and efficacy profiles and convenient dosing, which make them ideal for treatment-naive patients.
Tibotec is a wholly owned subsidiary of Johnson & Johnson.
